Immix Biopharma (IMMX) Receivables (2024 - 2026)
Quarterly results put Receivables at $6.2 million for Q1 2026, up 264.71% from a year ago — trailing twelve months through Mar 2026 was $6.2 million (up 264.71% YoY), and the annual figure for FY2025 was $4.6 million, up 142.11%.
Immix Biopharma has reported Receivables over the past 3 years, most recently at $6.2 million for Q1 2026.
- Receivables reached $6.2 million in Q1 2026 per IMMX's latest filing, up from $4.6 million in the prior quarter.
- Across five years, Receivables topped out at $6.2 million in Q1 2026 and bottomed at $1.7 million in Q1 2025.
- Median Receivables over the past 3 years was $4.1 million (2025), compared with a mean of $3.8 million.
- The largest annual shift saw Receivables soared 142.11% in 2025 before it skyrocketed 264.71% in 2026.
- Over 3 years, Receivables stood at $1.9 million in 2024, then skyrocketed by 142.11% to $4.6 million in 2025, then soared by 34.78% to $6.2 million in 2026.
- Business Quant data shows Receivables for IMMX at $6.2 million in Q1 2026, $4.6 million in Q4 2025, and $4.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 4.97 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 5.73 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Immix Biopharma | 476.17 Mn | 476.17 Mn | - | 6.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.20 Mn |
| Dec 31, 2025 | 4.60 Mn |
| Sep 30, 2025 | 4.60 Mn |
| Jun 30, 2025 | 3.60 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | 1.90 Mn |